sinc
sever
epizoot
avian
influenza
virus
aiv
transmit
human
caus
diseas
even
death
recent
emerg
sever
human
infect
aiv
china
rais
concern
effici
interperson
viral
transmiss
polygen
trait
viral
pathogen
manag
newli
emerg
strain
symptom
associ
viral
infect
differ
variou
ai
strain
newli
emerg
induc
sever
pneumonia
relat
complic
patient
subtyp
caus
conjunct
mild
respiratori
symptom
virul
tissu
tropism
virus
well
host
respons
contribut
pathogenesi
human
aiv
infect
sever
prevent
therapeut
approach
propos
combat
aiv
infect
includ
antivir
drug
inhibitor
neuraminidas
inhibitor
rna
polymeras
inhibitor
attach
inhibitor
signaltransduct
inhibitor
etc
articl
summar
recent
progress
research
epidemiolog
clinic
featur
pathogen
determin
avail
potenti
antivir
aiv
avian
influenza
viru
aiv
potenti
sourc
emerg
human
influenza
pandem
histor
sever
harm
influenza
pandem
origin
aiv
genet
reassort
human
avian
influenza
strain
happen
pandem
unpreced
emerg
human
infect
provid
first
evid
aiv
could
directli
transmit
poultri
human
sinc
februari
case
sever
human
infect
aiv
china
aiv
strain
consist
gene
three
aiv
strain
view
pandem
threat
avian
influenza
viru
aiv
influenza
viru
member
genu
orthomyxoviru
genom
aiv
consist
eight
minussens
singlestrand
rna
segreview
ment
encod
minimum
uniqu
viral
protein
current
classif
subtyp
base
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
date
ha
subtyp
nine
na
subtyp
describ
uniqu
genom
influenza
viru
recent
discov
bat
guatemala
one
remark
featur
influenza
virus
inclin
undergo
antigen
variat
antigen
drift
antigen
shift
antigen
drift
consist
rel
minor
mutat
alter
antigen
ha
na
occur
continu
result
select
pressur
host
immun
antigen
shift
genet
reassort
eight
gene
segment
result
appear
novel
hana
combin
human
popul
littl
immun
major
peopl
immunolog
novel
strain
strain
transmit
effici
human
human
influenza
pandem
may
occur
aquat
bird
reservoir
influenza
viru
subtyp
influenza
virus
infect
wild
andor
domest
bird
limit
sign
diseas
thu
two
author
contribut
equal
work
correspond
address
epidemiolog
three
differ
subtyp
aiv
confirm
capabl
infect
human
tabl
human
infect
aiv
primarili
mucou
membran
come
direct
contact
infecti
secret
excreta
infect
bird
contamin
poultri
product
main
infecti
rout
aiv
seem
via
upper
respiratori
tract
conjunctiva
direct
introduct
lower
respiratori
tract
may
occur
massiv
exposur
cull
oper
infect
poultri
role
infect
rout
eg
gastrointestin
tract
remain
explor
first
warn
aiv
could
directli
transmit
avian
speci
human
occur
hong
kong
result
infect
death
hpai
influenza
virus
found
endem
poultri
provinc
southern
china
fact
support
longterm
surveil
sinc
hpai
spread
asia
europ
africa
far
east
poultri
trade
migratori
bird
movement
case
human
infect
confirm
past
year
fatal
rate
approxim
children
young
adult
appear
suscept
viru
subtyp
aiv
caus
multipl
case
human
infect
sinc
canada
china
itali
netherland
unit
state
unit
kingdom
hpai
viru
found
transmit
duck
human
case
human
infect
confirm
one
patient
die
sever
pneumonia
sever
aiv
strain
includ
hpai
lpai
lpai
sporad
outbreak
recent
year
result
mild
ill
human
latest
lpai
outbreak
china
howev
caus
sever
death
due
sever
pneumonia
relat
complic
although
type
aiv
still
zoonot
may
like
develop
interperson
pandem
virus
preferenti
bind
sa
andor
mammalian
adapt
trait
protein
sinc
first
human
infect
lpai
detect
hong
kong
viru
infrequ
isol
human
symptom
associ
infect
gener
mild
evid
humantohuman
transmiss
main
clinic
manifest
aiv
infect
depend
viral
subtyp
lpai
eg
hpai
strain
caus
asymptomat
mild
symptom
conjunct
uncompl
influenzalik
ill
human
current
human
infect
lpai
typic
influenzalik
ill
eg
fever
cough
appear
earli
cours
diseas
blood
biochemistri
test
identifi
aspart
aminotransferas
ast
lactat
dehydrogenas
ldh
creatin
kinas
ck
level
significantli
increas
white
blood
cell
count
normal
slightli
decreas
patient
progress
sever
pneumonia
follow
acut
respiratori
distress
syndrom
ard
final
die
multiorgan
failur
interstiti
infiltr
lobar
infiltr
collapseconsolid
could
observ
chest
radiograph
onset
ill
clinic
featur
infect
comprehens
describ
gao
et
al
hpai
infect
onset
diseas
occur
median
exposur
initi
symptom
diseas
also
influenzalik
dyspnea
could
observ
patient
extrapulmonari
symptom
conjunct
gastrointestin
symptom
eg
abdomin
pain
diarrhea
vomit
occasion
occur
complic
includ
rey
syndrom
pulmonari
hemorrhag
mani
patient
progress
sever
pneumonia
rapidli
develop
ard
diseas
onset
final
die
multiorgan
failur
compar
survivor
hpai
infect
fatal
case
like
present
leukopenia
lymphopenia
thrombocytopenia
elev
level
ast
ldh
ck
abnorm
chest
radiograph
find
primari
histopatholog
find
fatal
human
infect
extens
infiltr
lung
dissemin
intravascular
coagul
multiorgan
failur
lung
pneumocyt
primari
target
infect
result
diffus
alveolar
damag
interstiti
fibrosi
hyalin
membran
format
patchi
interstiti
lymphoplasmacyt
infiltr
bronchiol
squamou
metaplasia
pulmonari
congest
vari
degre
hemorrhag
hpai
viru
also
infect
multipl
organ
addit
lung
postmortem
find
patient
die
infect
show
edema
degener
myocyt
heart
extens
hepat
central
lobular
necrosi
extens
acut
tubular
necrosi
kidney
dissemin
intravascular
coagul
cerebr
involv
fatal
case
aiv
infect
pregnant
woman
reveal
viral
infect
brain
placenta
fetu
addit
system
cytokin
activ
result
hemophagocyt
syndrom
lymphoid
deplet
skelet
muscl
fiber
necrosi
viral
load
aiv
vari
respiratori
secret
tissu
plasma
cerebrospin
fluid
fece
respiratori
secret
tissu
commonli
highest
viral
load
viru
detect
patient
infecti
viru
viral
rna
detect
fece
intestin
suggest
viru
sometim
replic
gastrointestin
tract
intestin
involv
viru
infect
may
explain
common
occurr
diarrhea
viral
rna
plasma
often
detect
patient
fatal
diseas
nonfat
diseas
indic
level
viral
replic
may
influenc
outcom
high
viral
load
also
correl
increas
host
respons
patient
hpai
infect
rare
detect
viral
rna
respiratori
tract
week
sever
diseas
associ
aiv
infect
human
could
caus
varieti
mechan
includ
viral
dissemin
differ
tissu
tropism
host
respons
gener
host
respons
aiv
complic
includ
apoptosi
autophagi
well
immun
respons
innat
humor
cellmedi
autophagi
tightli
regul
homeostat
process
selfdigest
unwant
cellular
subcompon
suggest
respons
lung
injuri
aiv
infect
autophag
death
alveolar
epitheli
cell
may
also
respons
high
mortal
rate
infect
autophagyblock
agent
appli
prophylact
therapeut
mice
significantli
increas
surviv
rate
allevi
lung
injuri
caus
infect
accumul
evid
suggest
virusinduc
cytokinechemokin
dysregul
also
play
signific
role
pathogenesi
aiv
infect
respiratori
epitheli
cell
macrophag
primari
innat
immun
cell
involv
aiv
infect
pronounc
activ
proinflammatori
cytokinechemokin
cascad
prolong
period
inflammatori
respons
contribut
tissu
damag
persist
system
inflammatori
respons
syndrom
furthermor
cytokin
sensit
neighbor
cell
upregul
rigi
amplifi
cytokin
cascad
hpai
infect
appear
cytokin
respons
may
driven
highlevel
viral
replic
plasma
level
macrophageand
neutrophilattract
chemokin
well
proand
antiinflammatori
cytokin
higher
patient
hpai
infect
compar
level
patient
convent
influenza
infect
note
mediat
cytokin
found
serum
sampl
swineorigin
influenza
viru
soiv
infect
patient
defici
treatment
monoclon
antibodi
significantli
allevi
acut
lung
injuri
induc
soiv
viru
mice
addit
suggest
enhanc
proinflammatori
outcom
antivir
respons
human
cell
thu
monoclon
antibodi
may
help
reduc
sever
lung
injuri
induc
aiv
infect
suppress
interferon
also
involv
human
aiv
infect
hpai
found
attenu
express
well
level
type
ifn
subsequ
substanti
delay
phosphoryl
induct
ifnstimul
gene
isg
vitro
viral
protein
appear
main
culprit
correl
complet
suppress
known
viral
inflammasom
activ
addit
cytokin
respons
apoptosi
autophagi
humor
cell
immun
respons
also
involv
aiv
infect
surprisingli
although
respons
exhibit
antivir
activ
affect
viru
replic
although
immun
cell
exclud
play
role
dissemin
viru
vivo
virul
aiv
determin
constel
gene
gene
play
import
role
viral
replic
andor
pathogen
also
potenti
target
antivir
agent
ha
protein
ha
influenza
viru
protein
play
crucial
role
earli
stage
viral
life
cycl
bind
viral
receptor
mediat
fusion
process
influenza
viru
infect
begin
ha
bind
sialic
acid
sa
link
glycoprotein
receptor
surfac
target
cell
usual
aiv
preferenti
bind
link
sa
locat
mainli
type
ii
pneumocyt
alveolar
macrophag
noncili
cuboid
epitheli
cell
termin
bronchiol
human
influenza
virus
tend
use
link
sa
receptor
upper
respiratori
tract
human
aiv
infect
human
airway
epithelium
replic
limit
due
nonoptim
cellular
tropism
thu
adapt
aiv
howev
sever
aiv
strain
increas
bind
humantyp
receptor
isol
human
still
prefer
bind
aviantyp
receptor
perform
effici
humantohuman
transmiss
lpai
strain
isol
human
also
report
dual
bind
affin
type
receptor
obviou
interperson
intermammalian
transmiss
observ
strain
eight
amino
acid
delet
ha
rbd
two
specif
mutat
also
suggest
contribut
increas
bind
affin
human
receptor
mutat
identifi
clinic
isol
five
amino
acid
substitut
four
reassort
ha
viru
effici
support
airborn
viral
transmiss
among
mammal
posttransl
cleavag
subunit
activ
membran
fusion
potenti
ha
crucial
infect
viru
lpai
virus
possess
singl
arginin
residu
cleavag
site
ha
cleav
extracellular
trypsinlik
proteas
restrict
respiratori
tract
contrast
hpai
virus
contain
motif
multipl
basic
amino
acid
residu
equival
cleavag
site
permit
cleav
ubiquit
distribut
intracellular
proteas
furinlik
proteas
enabl
system
infect
notabl
circul
viru
possess
singl
arginin
ha
cleavag
site
yet
caus
sever
diseas
death
human
fact
indic
exist
multibas
cleavag
site
essenti
high
pathogen
aiv
human
gene
may
also
involv
flexibl
loop
structur
cleavag
site
critic
effici
cleavag
rel
stabl
alphahelix
structur
flexibl
cleavag
loop
eg
key
residu
hidden
behind
helix
inaccess
cleavag
site
may
contribut
low
pathogen
subtyp
aiv
natur
alphahelix
element
might
also
provid
new
opportun
influenza
viru
inhibitor
design
evolutionari
balanc
ha
na
protein
aiv
essenti
entri
releas
process
viru
result
mutat
within
activ
site
either
ha
na
affect
enzymat
activ
protein
exampl
virus
sustain
circul
poultri
possess
addit
glycosyl
site
shorten
na
stalk
might
enhanc
virul
aiv
mammal
delet
five
amino
acid
na
stalk
region
also
found
circul
isol
may
help
explain
unusu
high
virul
strain
polymeras
pa
nucleocapsid
protein
np
togeth
form
rnp
critic
viru
replic
virul
determin
host
restrict
sever
amino
acid
eg
posit
eg
posit
basic
molecular
determin
associ
enhanc
polymeras
activ
pathogen
viru
mammal
mutat
posit
viru
promot
higher
viral
yield
upper
lower
respiratori
tract
mice
also
result
convers
nonleth
viru
lethal
one
similar
mutat
also
observ
current
circul
viru
produc
altern
read
frame
gene
nonstructur
accessori
protein
influenza
virus
protein
express
almost
avian
influenza
strain
strain
human
swine
host
form
prematur
truncat
either
cor
ntermin
end
shown
specif
target
sensit
alveolar
macrophag
apoptot
stimuli
presenc
intact
protein
also
found
contribut
viral
pathogen
mutat
led
delay
activ
ifnstimul
gene
increas
cytokinechemokin
level
mice
due
inhibit
earli
type
ifn
respons
level
mitochondri
antivir
signal
protein
mav
precis
function
protein
remain
unclear
research
protein
indic
protein
strainspecif
function
could
vari
differ
host
multifunct
nonstructur
rnabind
protein
critic
inhibit
ifn
product
antivir
effect
ifninduc
protein
dsrnadepend
protein
kinas
r
pkr
rnase
l
mutat
dramat
increas
virul
strain
mice
also
found
circul
viru
substitut
associ
mutat
ha
na
contribut
pathogen
aiv
human
sever
safe
effect
drug
use
manag
human
avian
influenza
infect
agent
includ
neuraminidas
polymeras
attach
signaltransduct
inhibitor
well
ribavirin
arbidol
herb
sever
neuraminidas
inhibitor
approv
prophylaxi
therapeut
treatment
influenza
tabl
agent
still
studi
preclin
clinic
investig
review
basic
pharmacokinet
properti
support
use
agent
aiv
migrat
h
ion
interior
viral
particl
mediat
channel
allow
uncoat
viru
particl
endosom
two
commerci
avail
inhibitor
amantadin
rimantadin
tabl
wide
use
treatment
human
avian
influenza
infect
mani
year
shown
shorten
diseas
durat
facilit
symptom
resolut
unfortun
current
circul
anim
virus
includ
swineorigin
current
inhibitor
resist
due
overus
inhibitor
widespread
resist
strain
preclud
use
inhibitor
case
human
infect
resist
mutat
occur
mainli
transmembran
portion
protein
posit
result
enlarg
diamet
channel
pore
thu
reduc
bind
inhibitor
differ
subtyp
clade
aiv
exhibit
differ
frequenc
inhibitor
resist
exampl
case
clade
isol
substitut
frequenc
mutat
clade
rang
addit
case
isol
variat
seem
increas
adamantaneresist
influenza
virus
mediat
continu
select
drug
pressur
therefor
recommend
amantadin
rimantadin
use
prevent
treat
aiv
known
sensit
interestingli
one
studi
suggest
mutat
ha
protein
might
also
play
role
amantadin
resist
addit
sever
novel
inhibitor
includ
new
adamantan
deriv
biolog
agent
eg
annexin
shown
mark
activ
human
influenza
virus
whether
agent
could
replac
amantadin
rimantadin
influenza
viru
treatment
need
explor
viral
neuraminidas
na
enabl
progeni
viru
cleav
receptor
spread
cell
neuraminidas
inhibitor
cyclopentan
pyrrolidin
deriv
prevent
spread
influenza
block
releas
newli
form
particl
four
commerci
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
laninamivir
approv
use
human
first
two
wide
use
countri
effect
influenza
infect
particularli
oseltamivir
earli
administr
shorten
durat
ill
tabl
main
characterist
current
avail
antivir
npg
ness
also
facilit
symptom
resolut
neuraminidas
inhibitor
also
effect
differ
aiv
subtyp
vitro
tabl
studi
anim
model
demonstr
oseltamivir
given
treatment
prophylaxi
activ
avian
influenza
strain
protect
efficaci
influenc
virul
strain
dosag
treatment
initi
time
clinic
trial
also
suggest
oseltamivir
zanamivir
use
reduc
mortal
lethal
infect
resist
treatment
rare
emerg
therefor
recommend
two
agent
primari
intervent
treatment
prevent
human
aiv
infect
howev
continu
monitor
aiv
drug
suscept
need
oseltamivirresist
season
influenza
strain
spread
around
world
sinc
notabl
one
current
isol
substitut
associ
vitro
resist
neuraminidas
inhibitor
anoth
na
subtyp
aiv
mutat
also
confirm
lead
oseltamivirand
zanamivirresist
clinic
aiv
subtyp
tabl
presenc
na
substitut
two
patient
also
receiv
corticosteroid
treatment
result
treatment
failur
thu
crucial
assess
preval
drugresist
futur
influenza
surveil
among
newli
develop
neuraminidas
inhibitor
laninamivir
extrem
long
persist
time
lung
increas
prospect
longlast
antivir
effect
prevent
influenza
infect
singl
dose
influenza
polymeras
consist
sever
polypeptid
includ
pa
also
contribut
high
virul
aiv
human
therefor
novel
antivir
target
polymeras
anticip
reduc
replic
aiv
well
inhibit
sever
pathogen
induc
viru
current
influenza
rna
polymeras
inhibitor
divid
nucleosid
nonnucleosid
polymeras
inhibitor
fluorodeoxycytidin
analog
favipiravir
shown
activ
treatment
influenza
vitro
vivo
potent
inhibitor
among
fluorodeoxycytidin
analog
inhibit
variou
strain
hpai
lpai
inhibitori
concentr
ic
rang
mdck
cell
ip
could
protect
mice
lethal
hpai
infect
administ
h
viru
exposur
prodrug
need
convert
activ
form
competit
inhibit
rna
synthesi
activ
influenza
polymeras
effect
sever
strain
ic
rang
vitro
rang
oseltamivir
vivo
differ
deliveri
method
abl
protect
mice
lethal
infect
sever
polymeras
inhibitor
develop
aiv
infect
gtpase
induc
type
type
iii
ifn
inhibit
influenza
viru
infect
interact
ribonucleoprotein
complex
interf
viral
assembl
disrupt
interact
short
peptid
deriv
also
report
inhibit
viru
polymeras
sever
small
interf
rna
sirna
target
overlap
gene
found
reduc
virusassoci
cell
apoptosi
viru
titer
chicken
embryo
novel
compound
inhibit
influenza
viral
genom
replic
andor
transcript
padepend
manner
anoth
novel
compound
induc
ifn
product
inhibit
growth
influenza
virus
inhibit
viral
polymeras
function
subsequ
loss
express
viral
ifn
antagonist
although
efficaci
polymeras
inhibitor
need
examin
clinic
investig
lead
compound
result
develop
seri
novel
antiinfluenza
agent
target
viral
rna
polymeras
ribavirin
arbidol
long
recogn
broadspectrum
antivir
agent
virus
differ
famili
virus
resist
treatment
rare
observ
target
ribavirin
cellular
enzym
inosin
imp
dehydrogenas
involv
viral
rna
synthesi
cellular
biosynthesi
gtp
ic
ribavirin
rang
vitro
ribavirin
po
protect
mice
lethal
infect
clinic
efficaci
ribavirin
influenza
less
effect
adamantan
na
inhibitor
depend
deliveri
manner
aerosol
ribavirin
effect
elimin
influenza
viru
shorten
durat
ill
clinic
observ
oral
administ
ribavirin
howev
clinic
util
ribavirin
may
limit
due
risk
hemolyt
anemia
teratogen
prodrug
ribavirin
viramidin
may
improv
util
ribavirin
prodrug
similar
activ
season
influenza
virus
less
toxic
furthermor
viramidin
effect
protect
mice
lethal
influenza
even
drug
administ
drink
water
drug
phase
develop
hcv
treatment
arbidol
wide
use
russia
almost
year
mechan
arbidol
complic
membran
fusion
inhibit
immunomodulatori
activ
may
contribut
broad
antivir
effect
arbidol
shown
stabil
ha
caus
ph
unit
reduct
ph
requir
transit
low
ph
form
protein
recombin
arbidolresist
strain
possess
singl
amino
acid
substitut
subunit
abrog
activ
arbidol
arbidol
activ
aiv
rang
ic
valu
current
research
also
confirm
posttreat
arbidol
decreas
mortal
influenzainfect
mice
mitig
lung
lesion
format
reduc
viral
titer
furthermor
effici
protect
host
virusinduc
inflamm
modul
express
proinflammatori
cytokin
data
suggest
arbidol
might
also
effect
treatment
sever
aiv
infect
human
mention
influenza
viru
need
attach
sa
receptor
enter
host
cell
number
attach
inhibitor
develop
aiv
includ
sialidas
mimic
sialyl
glycopolym
hemagglutinin
inhibitor
sialidas
recombin
construct
inhal
bacteri
sialidas
prevent
attach
subsequ
infect
influenza
viru
remov
influenzareceptor
interact
shown
activ
infect
continu
shorter
treatment
human
airway
epithelium
model
studi
perform
lethal
mice
model
inhal
protect
mice
viral
infect
prophylact
therapeut
approach
phase
studi
season
pandem
influenza
complet
patient
given
inhal
show
signific
reduct
viral
load
symptom
improv
sialylglycopolym
hemagglutinin
inhibitor
eg
eb
peptid
ndfrskt
peptid
show
enhanc
bind
affin
ha
compar
normal
sa
allow
block
attach
aiv
fusion
inhibitor
tertbutyl
hydroquinon
tbhq
bound
hydrophob
pocket
form
interfac
ha
monom
consequ
inhibit
conform
rearrang
requir
membran
fusion
although
agent
still
preclin
studi
anticip
use
newli
emerg
influenza
strain
especi
aiv
asid
agent
directli
target
viral
protein
current
antivir
strategi
also
focu
intracellular
cascad
need
viral
replic
two
signal
pathway
requir
ensur
effici
viru
replic
consid
suitabl
target
antivir
approach
modul
rafmekerk
cascad
pathway
also
critic
cytokin
interferon
synthesi
influenza
infect
thu
inhibitor
target
cascad
may
inhibit
replic
viru
also
moder
sever
system
inflamm
aiv
infect
hypothesi
confirm
sever
laboratori
experi
vitro
vivo
although
efficaci
human
need
investig
howev
inhibitor
target
aspirin
routin
use
influenzalik
ill
mani
year
current
research
identifi
high
dosag
aspirin
effici
block
influenza
viru
replic
vitro
vivo
plan
use
drug
clinic
studi
administr
via
inhal
sever
antiinflammatori
agent
eg
statin
sphingosin
analog
also
receiv
attent
investig
howev
result
studi
mix
sometim
even
conflict
nonetheless
studi
promot
optim
agent
suggest
new
strategi
therapi
aiv
infect
herb
may
also
potenti
choic
aiv
treatment
chines
herb
recommend
author
chines
govern
pandem
herbal
medicin
contain
isati
tinctoria
l
lonicera
japonica
thunb
saposhnikovia
divaricata
turcz
schischk
bupleurum
chinens
dc
forsythia
suspensa
thunb
vahl
citru
reticulata
blanco
perilla
frutescen
l
britton
commonli
taken
formula
use
prophylact
therapeut
treatment
influenza
infect
number
clinic
trial
herb
treatment
influenza
conduct
systemat
review
util
herb
influenza
treatment
reveal
herbal
medicin
show
posit
effect
viral
shed
medicin
posit
effect
fever
resolut
relief
symptom
although
rigor
placebocontrol
random
trial
need
reach
conclus
mani
chines
herb
exhibit
benefici
immunomodulatori
effect
rapid
recoveri
viral
infect
might
effect
treatment
aiv
infect
recent
sever
activ
proteas
influenza
virus
transmembran
proteas
serin
member
hat
human
airway
trypsinlik
proteas
consid
potenti
drug
target
peptid
mimet
proteas
inhibitor
eg
bapa
suppress
cleavag
activ
ha
spread
viru
hatexpress
cell
serin
proteas
mediat
influenza
ha
cleavag
respons
influenza
viru
activ
agent
target
serin
proteas
eg
aprotinin
leupeptin
camostat
suppress
cleavag
ha
limit
reproduct
human
avian
influenza
virus
singl
arginin
ha
cleavag
site
anticip
agent
use
treatment
hpai
virus
eg
whose
hemagglutinin
possess
multiargininelysin
cleavag
site
also
sever
compound
target
protein
show
consider
antiinfluenza
potenti
exampl
inhibit
replic
spread
influenza
viru
revers
inhibit
interferon
mrna
product
rnase
ldepend
manner
cjun
ntermin
kinas
jnk
inhibitor
reduc
amplif
influenza
viru
indirectli
inhibit
support
function
